Review of Clinical Pharmacology and Pharmacokinetics – International Edition Volume 38 (2024) – Supplementary Issue 2

Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all estimated cases. Advanced RCC often carries poor prognosis due to its high metastases rate, the lack of early-warning signs, as well as its complex clinical manifestations and its resistance to chemotherapy. Continue reading

Review of Clinical Pharmacology and Pharmacokinetics – International Edition Volume 38 (2024) – Supplementary Issue 2

The lack of safe and effective antiepileptic drugs is a persistent issue that could be addressed through the repurposing or further development of commonly available drugs. Due to high accuracy, low effort, and high cost, it is best to begin the search for alternative treatments with a theoretical chemical study. Continue reading

Review of Clinical Pharmacology and Pharmacokinetics – International Edition – Volume 38 (2024) – Supplementary Issue 2

Network pharmacology as a “green approach”, predicting metabolite behaviours chemically and biologically and guiding biological experimental design, is a new strategy aiming to uncover the mechanism of action of natural products as drug candidates. Continue reading